Skip to main content Skip to section navigation Skip to footer
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
Kintara Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaboration
    • Advisors
  • Pipeline
    • Overview
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News & Events
    • Company Info
    • Stock Info
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

July 8, 2024 • 6:30 AM EDT

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

July 1, 2024 • 8:35 AM EDT

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 3, 2024 • 8:35 AM EDT

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

May 14, 2024 • 4:45 PM EDT

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

April 3, 2024 • 7:00 AM EDT

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

March 27, 2024 • 9:00 AM EDT

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

February 14, 2024 • 4:07 PM EST

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

February 12, 2024 • 9:00 AM EST

Kintara Therapeutics Announces Review of Strategic Alternatives

December 7, 2023 • 9:00 AM EST

Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

December 5, 2023 • 9:00 AM EST
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 37
  • Next Pagearrow_forward
rss_feed News RSS
©2025 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences